# A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

> **NCT05238597** · PHASE2 · COMPLETED · sponsor: **Aramis Biosciences, Inc.** · enrollment: 207 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** A197 Ophthalmic Solution
- **DRUG:** A197 Vehicle Control
- **DRUG:** Active Comparator

## Key facts

- **NCT ID:** NCT05238597
- **Lead sponsor:** Aramis Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-25
- **Primary completion:** 2023-01-24
- **Final completion:** 2023-01-24
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238597, "A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05238597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*